Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock
Portfolio Pulse from Benzinga Insights
United Therapeutics (NASDAQ:UTHR) has been analyzed by 4 analysts, showing a mix of bullish to indifferent ratings. The average 12-month price target is $288.25, marking a 35.33% increase from the previous target of $213.00. Analysts from Wedbush, HC Wainwright & Co., Goldman Sachs, and Leerink Partners have provided ratings and price targets, reflecting varied expectations for UTHR's performance. The company, focusing on pulmonary arterial hypertension treatments, shows a revenue growth of 18.1% but falls below industry averages in market capitalization, net margin, ROE, and ROA.
February 22, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics receives mixed analyst ratings with an updated average 12-month price target of $288.25, indicating a positive outlook on its stock price.
The mixed analyst ratings with a significant increase in the average 12-month price target suggest a positive short-term outlook for UTHR's stock price. The company's strong revenue growth is a positive indicator, although challenges in market capitalization, net margin, ROE, and ROA may pose risks. The detailed analysis by analysts from reputable firms further supports the potential for stock price appreciation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100